AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39151476 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 303
Study 39151476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 39151647 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy based on co-formulated darunavir/ritonavir (800/100 mg) plus lamivudine (300 mg)
Number of subjects: 336
Study 39151647 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with darunavir/ritonavir plus tenofovir/emtricitabine (300/200 mg) or tenofovir/lamivudine (300/300 mg)
Number of subjects: 336
Study 39151647 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 336
Study 39151715 — intervention group
Group type: EXPERIMENTAL
Intervention: ESC 0 to 1-hour pathway
Number of subjects: 100
Study 39151715 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of care testing (POCT) for high sensitivity troponin measurement
Number of subjects: 100
Study 39151715 — intervention group
Group type: COMPARATOR
Intervention: ESC 0 to 3-hour pathway
Number of subjects: 100
Study 39151756 — intervention group
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs (REP)
Number of subjects: 1690
Study 39151756 — intervention group
Group type: EXPERIMENTAL
Intervention: REP + Coaching + Facilitation
Number of subjects: 1690
Study 39151756 — intervention group
Group type: COMPARATOR
Intervention: Coaching
Number of subjects: 1690
Study 39151756 — intervention group
Group type: COMPARATOR
Intervention: Facilitation
Number of subjects: 1690
Study 39151920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis CU1 (BSCU1) supplementation (2 × 10^9 cfu/day) for 4 weeks
Number of subjects: 88
Study 39152028 — intervention group
Group type: COMPARATOR
Intervention: Low-dose intra-erythrocyte dexamethasone sodium phosphate (approximately 5-10 mg)
Number of subjects: 164
Study 39152028 — intervention group
Group type: COMPARATOR
Intervention: High-dose intra-erythrocyte dexamethasone sodium phosphate (approximately 14-22 mg)
Number of subjects: 164
Study 39152028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 39152028 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (low-dose, high-dose, placebo)
Number of subjects: 164
Study 39152223 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding to induce 5-7% weight gain
Number of subjects: 35
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfusion of red blood cells (RBC)
Number of subjects: 176
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: MELD score increase
Number of subjects: 176
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin concentration increase
Number of subjects: 176
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of ascites
Number of subjects: 176
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: A10FIBTEM measurement increase
Number of subjects: 176
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold ischemia time increase
Number of subjects: 176
Study 39152310 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-reperfusion syndrome presence
Number of subjects: 176
Study 39152361 — intervention group
Group type: EXPERIMENTAL
Intervention: With R septa (n=10, 12.7%)
Number of subjects: 79
Study 39152361 — intervention group
Group type: COMPARATOR
Intervention: Without R septa (n=69, 87.3%)
Number of subjects: 79
Study 39152408 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based antenatal care (G-ANC)
Number of subjects: 1285
Study 39152467 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized rTMS targeting the primary motor cortex of the lower limb (motor priority group)
Number of subjects: 60
Study 39152467 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized rTMS over the left dorsolateral prefrontal cortex (cognitive priority group)
Number of subjects: 60
Study 39152467 — intervention group
Group type: COMPARATOR
Intervention: Active comparator: bilateral rTMS of the primary motor cortex of the upper limb
Number of subjects: 60
Study 39152477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) group
Number of subjects: 2212
Study 39152477 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DM and coronary microvascular dysfunction (CMD)
Number of subjects: 2212
Study 39152477 — intervention group
Group type: EXPERIMENTAL
Intervention: DM and CMD combination
Number of subjects: 2212
Study 39152477 — intervention group
Group type: COMPARATOR
Intervention: Non-DM group
Number of subjects: 2212
Study 39152484 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed psychological intervention consisting of six 10-min video modules addressing cognitive, emotional, and interpersonal aspects of infertility-related distress.
Number of subjects: 21
Study 39152484 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed psychological intervention
Number of subjects: 21
Study 39152487 — intervention group
Group type: EXPERIMENTAL
Intervention: SME tool (web-based intervention)
Number of subjects: 0
Study 39152487 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study 39152983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordella Pulmonary Artery sensor
Number of subjects: 456
Study 39152986 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Care (HIC)
Number of subjects: 1078
Study 39152986 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1078
Study 39153000 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Financial Wellness Scale
Number of subjects: 126
Study 39153000 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe financial distress group (n=26)
Number of subjects: 126
Study 39153000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 126
Study 39153060 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab treatment (interleukin-23p19 subunit inhibitor)
Number of subjects: 329
Study 39153127 — intervention group
Group type: EXPERIMENTAL
Intervention: High NOTCH1 mRNA expression in tumors (n=86)
Number of subjects: 1270
Study 39153127 — intervention group
Group type: EXPERIMENTAL
Intervention: High NOTCH1 mRNA expression
Number of subjects: 1270
Study 39153158 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust Based Relational Intervention (TBRI®)
Number of subjects: 0
Study 39153426 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat yogurt (12 oz/day)
Number of subjects: 39
Study 39153426 — intervention group
Group type: COMPARATOR
Intervention: Soy pudding control snack
Number of subjects: 39
Study 39153490 — intervention group
Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (3 doses of 9×10^6 sporozoites)
Number of subjects: 290
Study 39153490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 39153491 — intervention group
Group type: EXPERIMENTAL
Intervention: CADe-assisted colonoscopy
Number of subjects: 2032
Study 39153491 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 2032
Study 39153572 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligoasthenospermia (n = 405)
Number of subjects: 1131
Study 39153572 — intervention group
Group type: COMPARATOR
Intervention: Normospermia (n = 726)
Number of subjects: 1131
Study 39153751 — intervention group
Group type: EXPERIMENTAL
Intervention: SQ-LNS only
Number of subjects: 2291
Study 39153751 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth charts only
Number of subjects: 2291
Study 39153751 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth charts + SQ-LNS
Number of subjects: 2291
Study 39153751 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2291
Study 39153752 — intervention group
Group type: EXPERIMENTAL
Intervention: MO care (231 patients)
Number of subjects: 422
Study 39153752 — intervention group
Group type: COMPARATOR
Intervention: CA care (191 patients)
Number of subjects: 422
Study 39153754 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention of decision-supported electronic health records and non-physician care coordinator
Number of subjects: 1146
Study 39153779 — intervention group
Group type: EXPERIMENTAL
Intervention: rfhSP-D (1 mg/kg, 2 mg/kg, or 4 mg/kg)
Number of subjects: 24
Study 39153779 — intervention group
Group type: COMPARATOR
Intervention: Routine surfactant replacement therapy
Number of subjects: 24
Study 39153787 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nutritional support
Number of subjects: 445
Study 39153787 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 445
Study 39153792 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training + usual care
Number of subjects: 150
Study 39153792 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training + usual care
Number of subjects: 150
Study 39153792 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups (Resistance training or Aerobic training) followed by EBS + usual care
Number of subjects: 150
Study 39153792 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 39153792 — intervention group
Group type: COMPARATOR
Intervention: Usual care during 40-week follow-up
Number of subjects: 150
Study 39153816 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein group (2.0 g/kg per day)
Number of subjects: 935
Study 39153816 — intervention group
Group type: COMPARATOR
Intervention: Standard protein group (1.3 g/kg per day)
Number of subjects: 935
Study 39153818 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside (30 mg total, six 5 mg tablets)
Number of subjects: 293
Study 39153818 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg, one tablet)
Number of subjects: 293
Study 39153818 — intervention group
Group type: EXPERIMENTAL
Intervention: Emodepside
Number of subjects: 293
Study 39153818 — intervention group
Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 293
Study 39153817 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE)
Number of subjects: 229
Study 39153817 — intervention group
Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 229
Study 39153911 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-SXB (sodium oxybate) 9 g at week 13
Number of subjects: 212
Study 39153911 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 39153911 — intervention group
Group type: EXPERIMENTAL
Intervention: ON-SXB (sodium oxybate)
Number of subjects: 212
Study 39153979 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-ARDS
Number of subjects: 8117
Study 39153979 — intervention group
Group type: COMPARATOR
Intervention: CLASSIC-ARDS
Number of subjects: 8117
Study 39153977 — intervention group
Group type: EXPERIMENTAL
Intervention: Muay Thai (MT) training for 12 weeks, 3 times a week, 60 minutes per session.
Number of subjects: 50
Study 39153977 — intervention group
Group type: COMPARATOR
Intervention: Functional training (FT) for 12 weeks, 3 times a week, 60 minutes per session.
Number of subjects: 50
Study 39154071 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiplex real-time PCR plus conventional microbiological testing
Number of subjects: 242
Study 39154071 — intervention group
Group type: COMPARATOR
Intervention: Conventional microbiological testing alone
Number of subjects: 242
Study 39154085 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT) for ELVO
Number of subjects: 81
Study 39154085 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteomic analysis of 184 proteins from Olink proteomic (92 Cardiometabolic and 92 Inflammation panels)
Number of subjects: 81
Study 39154169 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting programme intervention
Number of subjects: 823
Study 39154191 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to improve COVID-19 infection control best practices
Number of subjects: 136
Study 39154298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 1 (23% of the patient sample)
Number of subjects: 1360
Study 39154298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 2 (39% of the patient sample)
Number of subjects: 1360
Study 39154298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 3
Number of subjects: 1360
Study 39154298 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster 4 and 5
Number of subjects: 1360
Study 39154298 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient clusters
Number of subjects: 1360
Study 39154299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorber CytoSorb (CS)
Number of subjects: 15
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback present, maximal intensity
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback present, submaximal intensity
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback absent, maximal intensity
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback absent, submaximal intensity
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback present
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback absent
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal intensity
Number of subjects: 84
Study 39154305 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal intensity
Number of subjects: 84
Study 39154316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg bolus
Number of subjects: 86
Study 39154316 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1 mcg/kg bolus
Number of subjects: 86
Study 39154316 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 86
Study 39154316 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 86
Study 39154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline pathogenic variants (PV) identified through sequencing of 250 cancer-related genes.
Number of subjects: 288
Study 39154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline pathogenic variants classified as ESCAT X.
Number of subjects: 288
Study 39154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Actionable variants classified as ESCAT I-A/II-A.
Number of subjects: 288
Study 39154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental findings of PVs in cancer-predisposition genes.
Number of subjects: 288
Study 39154486 — intervention group
Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance (VUS).
Number of subjects: 288
Study 39154597 — intervention group
Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 92
Study 39154808 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 100
Study 39154808 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS)
Number of subjects: 100
Study 39154808 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS and NRS correlation
Number of subjects: 100
Study 39154808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bland-Altman method
Number of subjects: 100
Study 39154860 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS (10, 40, or 100 mg/ml) with pro re nata refill-exchanges
Number of subjects: 555
Study 39154860 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml with fixed refill-exchanges every 24 weeks (PDS Q24W)
Number of subjects: 555
Study 39154860 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS Q24W from day 1
Number of subjects: 555
Study 39155155 — intervention group
Group type: EXPERIMENTAL
Intervention: Talquetamab
Number of subjects: 0
Study 39155367 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of HSOG Guidelines on labor management, training on cardiotocography interpretation, and emergency management in vaginal deliveries.
Number of subjects: 20000
Study 39155367 — intervention group
Group type: COMPARATOR
Intervention: Initial observation and recording of routine practice (cesarean section, vaginal birth, maternal and perinatal morbidity and mortality).
Number of subjects: 20000
Study 39155367 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback and performance monitoring for participating units during the intervention period.
Number of subjects: 20000
Study 39155425 — intervention group
Group type: COMPARATOR
Intervention: Non-DTG regimens
Number of subjects: 313
Study 39155425 — intervention group
Group type: EXPERIMENTAL
Intervention: DTG regimens
Number of subjects: 313
Study 39155576 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative anthropometric measures (waist-to-height ratio)
Number of subjects: 1116
Study 39155576 — intervention group
Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 1116
Study 39155700 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS-1780 (5, 10, 20, 40, 60, and 80 mg)
Number of subjects: 58
Study 39155700 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS-1780 (10, 20, and 40 mg) once daily for 7 days
Number of subjects: 58
Study 39155700 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS-1780
Number of subjects: 58
Study 39155700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 39155737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Number of subjects: 2282
Study 39155847 — intervention group
Group type: EXPERIMENTAL
Intervention: OSE2101 + Pembrolizumab
Number of subjects: 0
Study 39155847 — intervention group
Group type: EXPERIMENTAL
Intervention: OSE2101
Number of subjects: 0
Study 39155847 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study 39156216 — intervention group
Group type: EXPERIMENTAL
Intervention: Current shift work (SW)
Number of subjects: 344
Study 39156216 — intervention group
Group type: EXPERIMENTAL
Intervention: Former shift work (SW)
Number of subjects: 344
Study 39156216 — intervention group
Group type: COMPARATOR
Intervention: Never-shift workers
Number of subjects: 344
Study 39156699 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-automated module for radiolabeling; pH of 3.6 and precursor dose of 30 μg were used.
Number of subjects: 0
Study 39156699 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality control parameters tested in the fully-automated synthesis protocol.
Number of subjects: 0
Study 39157445 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for aspiration detection using voice analysis
Number of subjects: 198
Study 39157445 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model with learning rate of 3.00e-5 and batch size of 16
Number of subjects: 198
Study 39157445 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model with learning rate of 5.00e-5 and batch size of 32
Number of subjects: 198
Study 39157776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (6-weekly 1.5-hour sessions remotely delivered)
Number of subjects: 31
Study 39157776 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 31
Study 39157776 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 31
Study 39158071 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in B-cell ALL
Number of subjects: 46
Study 39158071 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in childhood T-cell ALL
Number of subjects: 46
Study 39158071 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in young adult T-cell ALL
Number of subjects: 46
Study 39158071 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in T-cell LL
Number of subjects: 46
Study 39158295 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical terbinafine hydrochloride 10% solution (MOB015B)
Number of subjects: 0
Study 39158353 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of electronic Patient Reported Outcome (ePRO) system
Number of subjects: 26
Study 39158353 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO system
Number of subjects: 26
Study 39158353 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PROMIS social functioning and grade 2 or more PRO-CTCAE interference of Abdominal Pain, Decreased Appetite, Dizziness and Shortness of Breath
Number of subjects: 26
Study 39158557 — intervention group
Group type: EXPERIMENTAL
Intervention: HFimpEF (improved ejection fraction)
Number of subjects: 447
Study 39158557 — intervention group
Group type: COMPARATOR
Intervention: non-HFimpEF (no improvement)
Number of subjects: 447
Study 39158569 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cTnI responders
Number of subjects: 59
Study 39158569 — intervention group
Group type: COMPARATOR
Intervention: Normal-cTnI responders
Number of subjects: 59
Study 39158584 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 booster dose (10 µg for 6 months-5 years; 25 µg for 6-11 years)
Number of subjects: 2672
Study 39158584 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 booster dose
Number of subjects: 2672
Study 39158589 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (Passeo-18 lux DCBs)
Number of subjects: 876
Study 39158670 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated subcutaneous immunoglobulin (fSCIG) 10%
Number of subjects: 253
Study 39158706 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse facilitator intervention
Number of subjects: 23
Study 39158741 — intervention group
Group type: EXPERIMENTAL
Intervention: KIND challenge intervention (acts of kindness at least once per week for four weeks)
Number of subjects: 4284
Study 39158741 — intervention group
Group type: EXPERIMENTAL
Intervention: KIND challenge intervention
Number of subjects: 4284
Study 39158741 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 4284
Study 39158761 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined subcision with platelet-rich plasma and microneedling
Number of subjects: 36
Study 39158761 — intervention group
Group type: COMPARATOR
Intervention: Combined subcision with saline and microneedling
Number of subjects: 36
Study 39158832 — intervention group
Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic myotomy (POEM)
Number of subjects: 118